Distribution Partnerships Inbiomotion already has established distribution relationships with Palex Medical SA covering Spain and Portugal, and with The Scientific Group for Sub Saharan Africa, plus a new collaboration with HyupJin for South Korea. This creates ready made channels for deploying MAFTest and accelerates market entry. Sales plays include joint marketing with partners, local regulatory support, and joint pilots to demonstrate value in target hospitals.

Clinical Validation The company has published AZURE results using its MAFTest and is an IRB Barcelona spin off focused on early stage breast cancer. This clinical credibility supports adoption by pathologists and oncologists and can shorten procurement cycles. Sales strategies include leveraging clinical data in pitches, presenting at oncology and pathology events, and providing hospital case studies to build trust.

Global Expansion Active international initiatives include partnerships in Korea and Sub Saharan Africa, signaling an intentional global growth plan. There is opportunity to tailor go to market strategies by region, including regulatory readiness and reimbursement considerations. Sales plays include mapping target markets with distributors, localizing stakeholder engagement, and planning regional pilots with hospital networks.

Targeted Buyers Primary buyers are pathologists and oncologists in early stage breast cancer, with decisions driven by relapse risk reduction and personalization of bisphosphonate therapy. MAFTest delivers a compelling value proposition around outcomes and potential cost savings for hospitals. Sales plays include payer focused value messaging, ROI tools, and offering bundled diagnostics with lab services.

Competitive Position As a nimble, research backed biotech with credible clinical data and selective partnerships, Inbiomotion can differentiate itself through faster adoption paths and potential cost advantages. Investor backing and a track record in breast cancer biomarkers enhance credibility for multi center programs. Sales opportunities include targeting hospitals for early adoption, expanding reference sites, and leveraging pilot contracts.